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Objectives: First-generation protease-inhibitors (PIs) have suboptimal efﬁcacy in GT-1 patients with
advanced liver disease, and patients experiencing treatment failure may require urgent retreatment. Our
objective was to analyse the real-life efﬁcacy of interferon (IFN)-free retreatment after PI-failure, and the
role of genotypic-resistance-testing (GRT) in guiding retreatment choice.
Methods: In this multi-centre observational study, patients retreated with IFN-free regimens after ﬁrst-
generation PI-failure (telaprevir-boceprevir-simeprevir) were included. Sustained-virological-response
(SVR) was evaluated at week 12 of follow-up. GRT was performed by population-sequencing.
Results: After PI-failure, 121 patients (cirrhotic¼ 86.8%) were retreated following three different strate-
gies: A) with ‘GRT-guided’ regimens (N¼ 18); B) with ‘AASLD/EASL recommended, not GRT-guided’
regimens (N¼ 72); C) with ‘not recommended, not GRT-guided’ regimens (N¼ 31). Overall SVR rate was
91%, but all 18 patients treated with ‘GRT-guided’ regimens reached SVR (100%), despite heterogeneity in
treatment duration, use of PI and ribavirin, versus 68/72 patients (94.4%) receiving ‘AASLD/EASL rec-
ommended, not GRT-guided’ regimens. SVR was strongly reduced (77.4%) among the 31 patients who
received a ‘not recommended, not GRT-guided regimen’ (p <0.01). Among 37 patients retreated with a PI,
SVR rate was 89.2% (33/37). Four GT-1a cirrhotic patients failed an option (C) simeprevir-containing
treatment; three out of four had a baseline R155K NS3-RAS. All seven patients treated with
paritaprevir-containing regimens reached SVR, regardless of treatment duration and performance of a
baseline-GRT.
Conclusion: Retreatment of PI-experienced patients can induce maximal SVR rates in real life. Baseline-
GRT could help to optimize retreatment strategy, allowing PIs to be reconsidered when chosen after a
RASs evaluation. V. Cento, Clin Microbiol Infect 2017;23:777.e1e777.e4
© 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
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The frequent development of NS3 resistance-associated sub-
stitutions (RASs) at failure limits retreatment options with
protease-inhibitors (PIs) for patients who previously failed a PI-blished by Elsevier Ltd. All rights reserved.
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EASL recommend use of a combination of an NS5A-inhibitor plus
sofosbuvir [1,2], without performing any baseline genotypic-
resistance-testing (GRT). However, in retreatment settings, GRT
can be clinically helpful in providing additional conﬁdence for
NS5A-inhibitor use, accounting for possible presence of natural
NS5A-RASs [1,3,4], and in evaluating alternative second-line regi-
mens besides those suggested by the guidelines.
Very few reports are available on real-life retreatment of PI-
experienced patients [5e7], and on the use, and utility, of base-
line HCV-GRT in this setting.
Methods
We analysed the efﬁcacy of several IFN-free retreatment stra-
tegies chosen for 121 patients with cirrhosis (86.8%) or advanced
ﬁbrosis (median (IQR) liver-stiffness: 10 (10-12) kPa) who previ-
ously failed a PI (boceprevir, N¼ 51; telaprevir, N¼ 69; simeprevir,
N¼ 1) plus pegylated-interferon and ribavirin (Table S1). This study
was conducted in accordance with the principles of the Declaration
of Helsinki. Approval by local ethics committees and informed
consents were obtained.
Baseline-GRT was performed at the clinician's discretion in 76/
121 patients by Sanger-sequencing on NS3-protease (aa 1e181),
NS5A domain I (aa 1-213), and/or NS5B (aa 1-591) genes, as
described elsewhere [8e11]. RASs were deﬁned according to pre-
viously published work [3,12,13].
Results
After a median (IQR) of 88 (49-120) weeks since PI-
discontinuation, 14/58 patients tested still presented NS3-RASs
able to confer cross-resistance to second-wave PIs (R155K, N¼ 6;
R155TþD168N, N¼ 1; Q80K, N¼ 4; V170A±A156S, N¼ 2;Fig. 1. SVR12 rates in patient subgroups. SVR12 rates obtained in protease-inhibitor experie
AASLD recommendations, or none of them. Rates are reported separately for each drug comb
resistance-associated substitutions at baseline are shown. 3D, paritaprevir/ritonavir, ombita
daclatasvir; EASL, European Association for the Study of the Liver; GRT, genotypic-resistance
SVR12, sustained virological response; RAS, resistance-associated substitution.V36Mþ R155K, N¼ 1). The prevalence of natural-RASs in NS5A and
NS5B was 11% (5/45 and 4/44, respectively). In addition, baseline-
GRT followed by phylogenetic-analysis disclosed four cases (5.3%)
of incorrect GT-1b assignation by commercial assays (three patients
were infected by GT-1a, and one by GT-4d).
Patients started retreatment with median (IQR) baseline HCV-
RNA of 5.9 (5.5e6.4) logIU/mL. One non-responder patient and 10
(8.3%) relapsers were observed, leading to a ﬁnal SVR12 rate of
90.9% (110/121). SVR12 rates were 85.1% (40/47) in GT-1a patients,
80.0% (8/10) in patients with baseline-RASs, and 90.6% (58/64) in
patients with baseline HCV-RNA >800 000 IU/mL. All non-cirrhotic
patients achieved SVR12 versus 89.5% of cirrhotic-patients (p 0.175,
Table S2). Fig.1 shows retreatment regimens in detail, along with
corresponding SVR12 rates.
According to the modality of retreatment choice, patients were
divided into three groups. The ‘GRT-guided’ group-A included 18
patients who either started a NS5A-containing recommended
regimen (N¼ 6), or a not-recommended PI-regimen (N¼ 12) based
on RASs proﬁles. The ‘AASLD/EASL recommended, not GRT-guided’
group-B included 72 patients who ‘switched’ DAA-class, and
received sofosbuvirþNS5A-inhibitorþ ribavirin, with no prior
NS5A-GRT. Lastly, the ‘not recommended, not GRT-guided’ group-C
included 31 patients, for whom neither GRT nor international
guidelines were followed.
Even if only 18 patients were retreated with ‘GRT-guided’ regi-
mens, this approach led to an optimal efﬁcacy (100% SVR12), similar
to ‘AASLD/EASL-recommended’ regimens in group-B (94.4% SVR12),
and much greater than the 77.4% (24/31) SVR12 rate observed in
group-C (p 0.011 by Fisher exact test; Table S2).
PIs were reused in 37 patients, and 33 (89.2%) reached SVR12. All
10 patients treated with sofosbuvirþ simeprevir after exclusion of
NS3-RASs (group-A) achieved SVR12, regardless of ribavarin
administration and treatment duration. SVR12 was also achieved in
the seven patients receiving paritaprevir/ritonavir þ ombitasvir þnced patients retreated with interferon-free regimens chosen according to GRT, EASL/
ination, ribavirin use and duration. The number of patients who relapsed, or presented
svir and dasabuvir; AASLD, American Association for the Study of Liver Diseases; DCV,
-test; IFN, interferon; LDV, ledipasvir; RBV, ribavirin; SIM, simeprevir; SOF, sofosbuvir;
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presence of baseline R155K NS3-RAS in one patient, conﬁrming the
efﬁcacy of this regimen as highlighted by previous real-life results
[7].
PI-free, NS5A-based regimens were also highly effective. An a
posteriori baseline-GRT performed in group-B, revealed one natural
NS5A-RAS in three GT-1b patients (L28M-L31M-Y93H, respec-
tively), and two NS5B-RASs (L159Fþ C316N) in another. Only the
patient with L28M failed a recommended sofosbu-
virþ daclatasvirþ ribavirin regimen, while the other two reached
SVR12 with a ribavarin-including, 24-week regimen.
The lowest SVR12 rates were observed in group-C among pa-
tients receiving sofosbuvirþ ribavarin (3/6, 50%), or GT-1a patients
receiving sofosbuvirþ simeprevir± ribavarin without prior NS3-
GRT (8/12, 66.7%). An a posteriori baseline-GRT performed in
three out of four of GT-1a simeprevir-failing patients revealed a
pre-existing R155K NS3-RAS. The other four patients in group-C
with baseline NS3-RASs (R155K¼ 2; Q80K¼ 1;
A156SþV170A¼ 1) treated for 24 weeks and/or with ribavarin
reached SVR12, plus a patient with Q80K receiving sofosbu-
virþ simeprevir for 12 weeks.
NS3- or NS5A-RASs were detected after retreatment in four out
of seven virological-failures tested (Table 1). Sofosbuvirþ ribavarin
failing-patients showed no RASs emergence, even though one GT-
1a had a natural L31M NS5A-RAS. Two group-B failing-patients
had the double NS5A-RASs L28Mþ Y93H, and two were not tested
for RASs.
Of the four GT-1a patients who failed sofosbuvirþ simeprevir
treatment, two showed Q80Lþ R155K or V36Mþ R155K RASs, one
was not retested after failure, and one had never performed any
NS3-GRT.Discussion
Baseline-GRT is widely used in retreatment settings in the USA,
thanks to the availability of commercial assays, but until recent
times Italy (as Europe) had poor access to these. Indeed, in our
study, even if some Italian centres offer internally validated assays
[8e11], in 69.5% of cases baseline-GRT was performed a posteriori
for research purposes only, and not used to guide retreatment de-
cisions. Nevertheless, GRT-guided regimens led to high SVR12 rates,
even when they included a PI, whose reuse is not supported by
current guidelines [1,2].Table 1
Resistance-associated substitution analysis in patients experiencing virological failure to
ID HCV
genotype
HCV-RNA at
baseline, IU/mL
IFN-free
treatment
Length,
weeks
Interval failure
to retreatment,
weeks
A
N
AASLD/EASL recommended, not GRT-guided
2286 1a 615 458 SOF/LDVþ RBV 24 157 V
M01 1b 2 084 319 SOF/LDVþ RBV 24 116 n
2135 1b 442 000 SOF/LDVþ RBV 12 n.a. V
219 1b 10 471 SOFþDCVþ RBV 24 119 e
Not recommended, not GRT-guided
330 1a 9 234 587 SOFþ SIMþ RBV 12 117 R
172 1a 116 116 SOFþ SIMþ RBV 24 78 n
PAO-2 1a 3 286 645 SOFþ SIM 24 68 V
2323 1a 1 393 000 SOFþ SIM 12 133 R
211 1a 1 104 189 SOFþ RBV 24 80 R
281 1b 157 383 SOFþ RBV 24 39 T
558 1a 2 731 632 SOFþ RBV 24 120 e
AASLD, American Association for the Study of Liver Diseases; DCV, daclatasvir; EASL, Eur
interferon; IU, International unit; LDV, ledipasvir; n.a., not available; PI, protease-inhibitGuidelines-recommended PI-free regimens were also highly
effective. The combination of sofosbuvirþ daclatasvirþ ribavirin
led to 94.4% (17/18) SVR12. Similarly, SVR12 rate was 95% (57/60)
with sofosbuvir/ledipasvirþ ribavarin combination, concordant
with the 96% SVR12 (74/77) from SIRIUS study in cirrhotic patients
[14], even if 59/60 of our patients were treated for 24weeks instead
of 12 [14]. Unfortunately, none of the three ledipasvir-failing pa-
tients had performed a baseline NS5A-GRT to assess possible
presence of natural NS5A-RASs.
A substantial proportion of patients (25.6%, 31/121) were
retreated with a variety of ‘not-recommended, not GRT-guided’
regimens, leading to the lowest SVR12 rates. This could be a
consequence of the time-gap between the approval of ﬁrst-
generation PIs and full availability of NS5A-inhibitors, when
retreatment choices for most urgent patients were limited to sub-
optimal regimens, such as sofosbuvirþ ribavirin (50% SVR12 (three
out of six), supporting previous real-life data [5]), and sofosbu-
virþ simeprevir± ribavirin without prior NS3-GRT in GT-1a pa-
tients (66.7% SVR12, 8/12).
Overall, even if ﬁrm conclusions cannot be drawn on the few
patients we analysed, our study encourages experienced labora-
tories, already present in several countries, to cooperate in offering
clinicians reliable GRTs to personalize retreatments for PI-
experienced patients, before considering not GRT-guided options.
GRT can disclose possible misclassiﬁcation of HCV-GT and can help
retreatment choice accounting for RASs-presence. This approach
would limit as much as possible the chances of second-line failures
and further development of multiresistant viruses, as well as high
costs of third-line therapies.Transparency declaration
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